Updated label introduces a 2-dose primary series starting at 2 months with a booster dose at 12-15 months, and with at least a 6-month interval between the primary series and booster dose1,2a
Internet Explorer is no longer supported.
To provide you with the best possible experience, please switch to a supported browser e.g.
has been added to your basket
Bexsero offers flexible dosing options, allowing for integration into the routine vaccination schedule1,2
aFirst dose should be given no earlier than 2 months of age. The safety and efficacy of Bexsero in infants less than 8 weeks of age has not yet been established. No data are available.
bIn case of delay, the booster should not be given later than 24 months of age.
cThe need for, and timing of, further booster doses has not yet been determined.
dNo data are available for adults above 50 years of age.
As with many vaccines, healthcare professionals should be aware that a temperature elevation may occur following vaccination of infants and children (less than 2 years of age). Prophylactic administration of antipyretics at the time of or closely after vaccination can reduce the incidence and intensity of postvaccination febrile reactions. Antipyretic medication should be initiated according to local guidelines in infants and children (less than 2 years of age).
Bexsero can be co-administered with any of the following vaccine antigens, either as a monovalent or as combination vaccines1,2:
Clinical studies suggest there is no clinically relevant immunological interference when Bexsero is given concomitantly with routine infant vaccines1,2
Bexsero is available as a white opalescent liquid suspension for injection in a prefilled syringe and comes as a 0.5-ml dose.
Prescribing information (Great Britain and Northern Ireland)
Summary of product characteristics and patient information leaflet (GB)
Summary of product characteristics and patient information leaflet (NI)
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline 0800 221 441
April 2022 I PM-GB-BEX-WCNT-200003 (V3.0)